EUCTR2018-001762-42-ES进行中（未招募）1 期
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 152
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •A patient must meet all of the following criteria to be eligible to participate in this study.
- •1. Be a male with an established clinical diagnosis of DMD and an out-of-frame deletion mutation of the DMD gene amenable to exon 51 skipping (for example, deletions of exons 45-50, 47-50, 48-50, 49-50, 50, 52, and 52-63).
- •2. Be aged 7 to 13 years, inclusive
- •3. Have achieved a mean 6-minute walk test (6MWT) distance of =300 and =450 meters (without assistance) at both the screening and baseline visits for the double-blind.
- •4. Have intact right and left biceps muscles (the preferred biopsy site) or an alternative upper arm muscle group that will allow for sufficiently sized (1 cm3) muscle biopsies to be obtained prior to and on treatment.
- •5. Have been on a stable dose or dose equivalent of oral corticosteroids for at least 24 weeks prior to randomization, and the dose is expected to remain constant (except for modifications to accommodate changes in weight) throughout the study.
- •6. Have stable pulmonary function (forced vital capacity =50% of predicted and no requirement for nocturnal ventilation) that, in the Investigator’s opinion, is unlikely to decompensate significantly over the duration of the study.
- •7. If sexually active, agree to use a male condom during such activity for the entire duration of the study and for 90 days after the last dose. The sexual partner must also use a medically acceptable form of contraceptive (ie, female oral contraceptives) during this timeframe.
- •8. Have (a) parent(s) or legal guardian(s) who is (are) able to understand and comply with all the study requirements.
- •9. Is willing to provide informed assent (if applicable) and has (a) parent(s) or legal guardian(s) who is (are) willing to provide written informed consent for the patient to participate in the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 152
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient who meets any of the following criteria will be excluded from this study:
- •1. Use of any pharmacologic treatment (other than corticosteroids) within 12 weeks prior to randomization that may have an effect on muscle strength or function. Growth hormone for short stature and testosterone for delayed puberty are permitted if an endocrinologist has documented the diagnosis and medical necessity of treatment and if the patient has been on a stable dose for at least 24 weeks prior to randomization.
- •2. Current or previous treatment with any other experimental pharmacologic treatment for DMD or any prior exposure to antisense oligonucleotide, gene therapy or gene editing; exceptions are listed in number 3 below.
- •3. Previous treatment with drisapersen, ezutromid, or domagrozumab in the last 24 weeks prior to study enrollment.
- •4. Major surgery within 3 months prior to randomization or planned surgery for any time during this study, except for allowed protocol-specified surgery, as applicable.
- •5. Presence of any other significant neuromuscular or genetic disease other than DMD (eg, dwarfism).
- •6. Presence of other clinically significant illness including significant cardiac, pulmonary, hepatic, renal, hematologic, immunologic, or behavioral disease or malignancy.
- •7. Has evidence of cardiomyopathy, as defined by LVEF <50% on the screening ECHO or the Fridericia’s correction formula (QTcF) =450 milliseconds based on the screening ECGs.
- •8. Prior or ongoing medical condition that could, in the Investigator’s opinion, adversely affect the safety of the patient, make it unlikely that the course of treatment would be completed, or impair the assessment of study results.
- •9. Is, in the Investigator’s opinion, unable or unwilling to comply with the study procedures.
研究者
相似试验
进行中（未招募）
1 期
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2018-001762-42-GBSarepta Therapeutics, Inc.122
进行中（未招募）
1 期
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyDuchenne Muscular DystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001762-42-CZSarepta Therapeutics, Inc.154
进行中（未招募）
1 期
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2018-001762-42-SISarepta Therapeutics, Inc.154
进行中（未招募）
1 期
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscular dystrophyMedDRA version: 20.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2018-001762-42-NLSarepta Therapeutics, Inc.154
招募中
3 期
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skippingmuscular dystrophy10028396DMDNL-OMON52516Sarepta Therapeutics, Inc.1